AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Brilinta Clinical Experience Investigation
Completed
- Conditions
- Acute Coronary Syndrome, Old Myocardial Infarction
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 663
- Registration Number
- NCT03212287
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
Type 2 Diabetes Mellitus Patients' Characteristics and Management by General Practitioners and Endocrinologists
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 907
- Registration Number
- NCT03209089
- Locations
- 🇷🇺
Research Site, Yoshkar-Ola, Russian Federation
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
Phase 1
Completed
- Conditions
- Malignant Solid TumorsLymphomaOvarian CancerProstate CancerBreast CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 49
- Registration Number
- NCT03205176
- Locations
- 🇨🇦
Research Site, Toronto, CA, Canada
China Ovarian Cancer BRCA Testing Study
Terminated
- Conditions
- Ovarian Cancer
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 29
- Registration Number
- NCT03203993
- Locations
- 🇭🇰
Research Site, Hong Kong, Hong Kong
A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies
Phase 1
Active, not recruiting
- Conditions
- Part1: Advanced B-cell MalignanciesPart2: r/rCLL and r/rMCLPart3: Untreated CLL
- Interventions
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT03198650
- Locations
- 🇯🇵
Research Site, Suita-shi, Japan
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 256
- Registration Number
- NCT03199053
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (Goserelin Acetate Implant) 10.8 mg and ZOLADEX® (Goserelin Acetate Implant) 3.6 mg in Chinese Patients With Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer
Completed
- Conditions
- Localized or Locally Advanced Prostate Cancer
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 308
- Registration Number
- NCT03193060
- Locations
- 🇨🇳
Research Site, Zhuhai, China
Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Other: Standard of Care
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 830
- Registration Number
- NCT03189875
- Locations
- 🇬🇧
Research Site, Sheffield, West Midlands, United Kingdom
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Biological: BenralizumabBiological: Placebo
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 695
- Registration Number
- NCT03186209
- Locations
- 🇨🇳
Research Site, Taoyuan City, Taiwan
To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease
Phase 4
Withdrawn
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT03181880
© Copyright 2025. All Rights Reserved by MedPath